Can pharmaceutical companies get opportunities from 2017 medical insurance catalog?

[market analysis of chinapharma.com] recently, the 2017 version of the medical insurance catalog was officially launched! The adjustment of the new version of the medical insurance catalog brings opportunities and challenges to pharmaceutical companies So what opportunities will the 2017 medical insurance catalog bring to pharmaceutical companies? (can pharmaceutical companies get opportunities from the 2017 medical insurance catalog? Picture source: Baidu picture) since 2014, there has been a call for the adjustment of the new version of the medical insurance catalog In the past two or three years, people from all walks of life and patients have given high hopes to the new version of the medical insurance catalog, hoping that it can be published as soon as possible to meet the increasing drug demand of the people, improve the diagnosis and treatment level of medical institutions, and achieve the goal of market return for new drug research and development of enterprises In the long run, the new version of the medical insurance catalog is delayed Until last year, the integration of two insurances was basically completed At the end of September, the Ministry of human resources and social security issued the work plan for the adjustment of the national basic medical insurance, work injury insurance and maternity insurance drug catalogue (Draft for comments), requiring the adjustment of the medical insurance drug catalogue to be completed by the end of 2016, and the dawn finally came Before the Spring Festival, the Ministry of human resources and social security asked the provincial medical insurance departments for opinions on the new version of the medical insurance catalogue, which is expected to come out in 2017 Finally, the official catalogue will be released With the expansion of the medical insurance catalogue, 339 new varieties have been added The new edition of the catalogue is the fourth edition since the establishment of the medical insurance system for urban employees in 1998 Before that, there are three editions of the Catalogue: 2000 edition, 2004 edition and 2009 edition The catalogue of the previous edition is 2009 edition, which contains 2196 varieties, 1164 medicines for western medicine, 987 medicines for Chinese patent medicine and 45 ethnic medicines In 2017 edition, there are 2535 varieties, 1297 for western medicine and 1238 for Chinese patent medicine (including 88 for ethnic medicine) In terms of the expansion range, the expansion range was basically the same in 2009, kept at about 16% Among them, 91 children's drugs have been added, 540 of which are clearly applicable to children in the drug catalog; 41 national drugs have been added, with a growth rate of 90%, which is significantly higher than other drugs; another 45 drugs to be negotiated, most of which are serious disease drugs or innovative drugs and varieties The expansion range of traditional Chinese medicine is large, more than 25%, especially the number of national medicine nearly doubled; the expansion range of Western medicine is 11.43% At the beginning, a friend worried about the expansion and compression under the pressure of medical insurance cost control was relieved Before July 31, there is still 15% room for adjustment of class B varieties at the provincial level According to the previous policies, each province (region, city) will adjust class B of the medical insurance catalog implemented in this region The adjusted quantity (including transfer in, transfer out, and adjustment of the Limited payment scope) is limited to 15% of the quantity of class B drugs at the national level With the expansion of the medical insurance catalogue, the proportion will remain unchanged The number of people's and social security departments in charge of the adjustment has also increased correspondingly According to the 2205 national class B catalogue, the number of adjustment in each region is about 330 This is the second chance for those varieties that have not yet entered the national catalog If we seize the chance of less than five months before July 31 to enter the provincial medical insurance, we will not be able to make up for them Opportunities for varieties out of the catalog: the era of payment by disease is not rigid For drugs for major and major diseases, the way of negotiation and entry one by one is adopted to enter the catalog The three varieties (tenofovir, gefitinib and exetinib) that were negotiated before have been listed in the catalogue this time, and the following new special drugs will also be listed in the catalogue through negotiation There are now 45 drugs to be negotiated In addition, for the drugs out of the catalog necessary for clinical emergency rescue and treatment of special diseases, a designated medical institution declaration system can be established, the corresponding audit management measures can be clarified, and reported to the higher human resources and social security department for the record The path setting of reimbursement for out of catalog varieties once again reflects the trend of light catalog and heavy supervision In particular, after the gradual introduction of payment by disease, the directory setting will not be as important as it is today For example, Zhejiang and Fujian have begun to try in this regard, and non-medical insurance varieties can be reimbursed as long as they meet the conditions Implementation time: later than August 31, 2017 PS: Catalog publishing is more than 11 o'clock Yesterday afternoon, the pharmaceutical stocks were all in full swing, especially the daily attention of several direct trading Patronize to look at the catalogue, wait for this small fairy to return to God to have been unable to buy Comrades, in this business, I didn't grasp the opportunity to collect money I guess I'm a fake medicine man! First hide and cry for a while, and then classify and count the data of medical insurance transfer out and in today.